Trial
NCT04398680
A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Multiple Myeloma
Intervention
Belantamab mafodotin
Why stopped
Sponsor Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-04